Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2015)
20 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 11, 2015
Slide 1: 2015 Annual General Meeting: CEO Address
For personal use only 2015 Annual General Meeting: CEO Address Dr Ross Macdonald, CEO, Cynata Therapeutics Limited November, 2015 Copyright and Confidential
Slide 2: Important information
Important information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 3: Cynata Therapeutics Ltd: Our Business
Cynata Therapeutics Ltd: Our Business For personal use only • ASX-listed company (CYP): November 2013 • ~1900 shareholders; 72.7m shares • Market cap: $32m (10 Nov ‘15) • 52 week range: $0.32-$1.44 • Focus: Stem cells and regenerative medicine – Commercial development of mesenchymal stem cells (MSC)
Slide 4: Why are Mesenchymal Stem Cells (MSCs) Important?
Why are Mesenchymal Stem Cells (MSCs) Important? For personal use only • Regenerative medicine is a revolution: potential to resolve unmet medical needs by addressing the underlying causes of disease • For example: heart attack (MI) - Sudden block of blood flow to a section of heart muscle - Most oc
Slide 5: Why are Mesenchymal Stem Cells (MSCs) Important?
Why are Mesenchymal Stem Cells (MSCs) Important? For personal use only Around 300* clinical trials underway with MSC therapies: *www.clinicaltrials.gov
Slide 6: Cymerus Competitive Advantage
Cymerus Competitive Advantage For personal use only • All current MSC-based medicines require donor derived material – Bone marrow – Adipose tissue – Placenta • Yield of MSCs is low, eg bone marrow harvest → ~20 thousand cells • Typical dose is >100 million cells • How can enough be produced?
Slide 7: Cymerus Competitive Advantage
Cymerus Competitive Advantage For personal use only • Cell expansion is used to create the quantities needed • Sounds simple? • BUT, MSCs exhibit changes during expansion, including altered phenotype, differentiation potential, gene expression profile • This occurs after as few as 13 population doub
Slide 8: Cymerus Competitive Advantage
Cymerus Competitive Advantage For personal use only MSC FACTORY • Multiple donors are not a practical solution for scalable manufacture • The solution lies in a different starting material to provide a virtually limitless source of MSCs without excessively expanding the MSCs in culture
Slide 9: Cynata's Cymerus technology
Cynata’s Cymerus™ technology For personal use only • Cymerus™ process uses iPSCs as starting material to mass produce MSCs • iPSCs: adult-derived cells with embryonic-like properties – effectively limitless expansion potential; ability to differentiate into any cell type • Inventors include: • Prof
Slide 10: Business Strategy
Business Strategy For personal use only • Cymerus technology is relevant to all potential therapeutic uses for MSCs • Logical to seek to partner the technology: resources, expertise, cash and market access • GMP manufacturing milestone in February facilitated commercial discussions • Vibrant deal la
Slide 11: Cynata Therapeutics: The Past Months
Cynata Therapeutics: The Past 12 Months For personal use only • Consolidating a commercial and clinical path: – December 2014 options exercised yielding $2.9m gross – Further validation through UWA, University of Sydney and Harvard/MGH collaborations – Validation of up-scaled manufacturing process i
Slide 12: Cynata: The Year Ahead
Cynata: The Year Ahead For personal use only • Important Development Milestones and Value Drivers: – Continue our partnering activities – Commence Phase 1 clinical trial of CYP-001 in GvHD – Vigorous investor relations campaign – Assessment of off-shore listing opportunities – Data from pre-clinical
Slide 13: Modified Stem Cells: The Future of Cancer Treatment
For personal use only A Next Generation Stem Cell Company Modified Stem Cells: The Future of Cancer Treatment Kilian Kelly, PhD Vice President, Product Development November 2015 Copyright and Confidential
Slide 14: Unmodified MSCs
Unmodified MSCs For personal use only • MSCs have a natural ability to: – home to sites of inflammation/injury – modulate the immune system MSCs: Immunoregulatory Properties1 – secrete bioactive molecules • Potentially effective for a wide range of conditions, including: – GvHD – Heart attacks, hear
Slide 15: Modified MSCs: rationale
Modified MSCs: rationale For personal use only • In addition to their natural functions, MSCs can also be modified to target other diseases, including cancer • MSCs are known to home to tumours, so MSCs modified to secrete cancer-killing toxins can be used to release anticancer agents where they are
Slide 16: The potential of modified MSCs
The potential of modified MSCs For personal use only 16
Slide 17: Cynata's collaboration with Harvard
Cynata’s collaboration with Harvard For personal use only • Cynata has commenced a collaboration with Dr Khalid Shah, of Massachusetts General Hospital, Harvard Medical School and Harvard Stem Cell Institute • Dr Shah’s team are pioneers of technology to modify stem cells to secrete cancer-killing t
Slide 18: Modified Stem Cells to Treat Brain Tumours
Modified Stem Cells to Treat Brain Tumours For personal use only Modified stem cells • Dr Shah’s group has previously found that modified stem cells killed cancer cells and prolonged survival in a clinically relevant animal model of glioblastoma (brain tumours) • Dr Shah’s group are now investigatin
Slide 19: Investor interest
Investor interest For personal use only • Immense investor interest in cell-based therapies for cancer • Last week, Cellectis announced data from a single patient treated with their cell-based therapy for leukaemia, which resulted in a ~60% increase in share-price • Note: Cynata’s new program target
Slide 20: Thank you for your attention
For personal use only Thank you for your attention
Cynata Therapeutics — Shareholder Meeting (November 2015) on 6ix